NASH trials recruiting in Ohio

All NASH trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
  NCT07221188 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Akron, Springboro
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Akron, Beavercreek, Brooklyn, Westlake
• A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
  NCT07221227 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Akron, Springboro, Westlake
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Akron, Springboro, Westlake
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Columbus, Dayton, Springboro, Westlake
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Akron, Cleveland, Dayton, Liberty Township
• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
  NCT07288138 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Akron, Dayton, Springboro, Westlake
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Akron, Cincinnati, Cleveland, Columbus
• Comparison of ALD, NASH, and Healthy Control Patients
  NCT03224949 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cleveland
• Evaluation of Non-Invasive Tests for Metabolic Liver Disease
  NCT07122700 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Columbus
• Fibrosis Lessens After Metabolic Surgery
  NCT06374875 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cleveland
• Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
  NCT06133101 · Phase: Phase 2 · Ages: 5 Years to 12 Years · Sex: All (male and female) · Ohio: Cincinnati
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  NCT06632457 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus, Mentor, Springboro, Westlake
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus, Mentor, Springboro, Westlake
• Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
  NCT05832229 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Ohio: Cleveland
• Milk Thistle Clinical Trial in Pediatric NAFLD
  NCT06477146 · Phase: Phase 2 · Ages: 9 Years to 22 Years · Sex: All (male and female) · Ohio: Cleveland